Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein

American Journal of Cardiology

Volumn 92, Issue 12, 2003, Pages 1414-1418

  Sager, Philip T ^a   Melani, Lorenzo ^a   Lipka, Leslie ^a   Strony, John ^a   Yang, Bo ^a   Suresh, Ramachandran ^a   Veltri, Enrico ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TREATMENT OUTCOME;

EID: 0346996795     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.048     Document Type: Article

References (22)

1. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., Perevozskaya I., von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 106:2002;1943-1948.
2. van Heek M., Farley C., Compton D.S., Hoos L., Davis H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 134:2001;409-417.
3. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 24:2003;729-741.
4. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1092-1097.
5. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., Cho M., Musliner T.A., Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1084-1091.
6. Davidson M., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134.
7. Ballantyne C. Ezetimibe efficacy and safety in clinical trials . Eur Heart J. 4:(suppl J):2002;J9-J18.
8. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial . Circulation. 107:2003;2409-2415.
9. Pietilä K.O., Harmoinen A.P., Jokiniitty J., Pasternack A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic therapy. Eur Heart J. 17:1996;1345-1349.
10. Ridker P.M., Rifai N., Rose L., Buring J., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347:2002;1557-1565.
11. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association . Circulation. 107:2003;499-511.
12. Plenge J.K., Hernandez T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., Eckel R.H. Simvastatin lowers C-reactive protein within 14 days an effect independent of low-density lipoprotein cholesterol reduction . Circulation. 106:2002;1447-1452.
13. Bays H.E., Stein E.A., Shah A.K., Maccubbin D.L., Mitchel Y.B., Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol. 90:2002;942-946.
14. Ridker P.M., Rifai N., Clearfield N., Downs J.R., Weis S.E., Miles S., Gotto A. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
15. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 45:1999;2136-2141.
16. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial . Lancet. 360:2002;7-22.
17. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
18. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
19. Kinlay S., Timms T., Clark M., Karam C., Bilodeau T., Ridker P.M., Rifai N., Carlson W., Lloyd-Jones D.M., Johnstone M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 89:2002;1205-1207.
20. Van Wissen S., Trip M.D., Smilde T.J., de Graaf J., Stalenhoef A.F.D., Kastelein J.J.P. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 165:2002;361-366.
21. van de Ree M.A., Huisman M.V., Princen H.M.G., Meinders A.E., Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 166:2003;129-135.
22. Heilbronn L.K., Noakes M., Clifton P.M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 21:2001;968-970.